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1. Introduction
Helicobacter pylori (H. pylori) is a Gram-negative microaerophilic spiral bacterium previously
known Campylobacterpylori. It has a significant attention since its isolation and characterisa‐
tion in 1983 [1]. It colonizes the gastrointestinal mucosa of its host in spite of a strong persistent
humoral and cellular immune response to H. pylori at the local and systemic level, the organism
persists for the lifetime of its host.
It is a pathogen, playing an important role in the aetiology of gastritis (especially active antral
gastritis). Gastritis is a histopathologic term characterized by chronic inflammation of the
stomach mucosa. It is classification based on the underlying cause (eg, H. pylori, that cause
atrophic gastritis, bile reflux, nonsteroidal anti-inflammatory drugs [NSAIDs], autoimmunity,
or allergic response) [2]. Gastritis is also classified as erosive or nonerosive based on the
severity of mucosal injury by endoscopy. Other classification is according to the site of
involvement (cardia, body, antrum). Histological classification is acute or chronic based on the
inflammatory cell type. Acute gastritis is characterized by PMN infiltration of the mucosa of
the antrum and body. Chronic gastritis implies some degree of atrophy or metaplasia. It
predominantly involves the antrum with subsequent loss of G cells and decreased gastrin
secretion or the corpus with loss of oxyntic glands, leading to reduced acid, pepsin, and
intrinsic factor [3, 4, 5].
H. pylori causes more than half of peptic ulcers worldwide. The bacterium causes peptic ulcers
by damaging the mucous membrane of the stomach and duodenum. Damage to the mucous
membrane causing stomach acid to get through to the sensitive lining layer. Together, the
stomach acid and H. pylori irritate the lining of the stomach or duodenum and cause an ulcer
[6].Ulcers in the stomach and duodenum result when the consequences of inflammation allow
stomach acid and the digestive enzyme pepsin to overwhelm the mechanisms that protect the
stomach and duodenal mucous membranes. The location of colonization of H. pylori, which
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affects the location of the ulcer, depends on the acidity of the stomach [7].The majority of
patients with duodenal ulcer (DU) are infected with H. pylori [8].
H. pylori infection is a major cause of gastric adenocarcinoma, specifically non-cardia gastric
cancer. H. pylori infection also causes gastric mucosa-associated lymphoid tissue (MALT)
lymphoma [9]. Some H. pylori bacteria had a toxin produced by a gene called cytotoxin-
associated gene A (cagA) injected into the junctions where cells of the stomach lining. This toxin
(known as CagA) alters the structure of stomach cells and allows the bacteria to attach to them
more easily. Long-term exposure to the toxin causes chronic inflammation [10]. Other type of
cancer is gastric MALT lymphoma is a rare type of non-Hodgkin lymphoma that is charac‐
terized by the slow multiplication of B lymphocytes. Normally, the lining of the stomach lacks
lymphoid tissue, but growth of this tissue is often stimulated in response to colonization of H.
pylori [11]. Nearly all patients with gastric MALT lymphoma show signs of H. pylori infection,
and the risk of developing this tumor is more than six times higher in infected people than in
uninfected people [12]
The prevalence of gastric cancers among H. pylori-infected patients varies between individuals,
countries, and geographic areas, H. pylori disease-related outcomes are believed to be deter‐
mined by interaction between host factors, bacterial factors, and their interaction with the
environment [13] produces different diseases in different persons. High and low acid secretion
rates probably contribute to duodenal ulceration and gastric carcinogenesis, respectively. H.
pyloriproducts and certain cytokines released in gastritis release gastrin from G-cells but inhibit
parietal cells. Also tumour necrosis factor alpha inhibits somatostatin-cells and interleukin 1
beta inhibits enterochromaffin-like cells. The net result is that antral gastritis tends to increase,
whilst corpus gastritis tends to decrease acid secretion. Corpus atrophy further lowers acid
through loss of parietal cells. Factors postulated to increase corpus gastritis include: host
genetics, early acquisition of bacteria, more aggressive strains, poor general health and diets
high in salt or lacking in antioxidant vitamins [14]. Other factor is environmental factors that play
an important role in the manifestation, course, and prognosis of diseases of H. pylori-induced
gastritis. This disease is the outcome of allelic group of a host and the microbial (microflora)
and physical environments. Host alleles predisposing to a disease in one genomic and/or
environmental surroundings may not be deleterious in other group, in addition to that microbes
can have different effects in different hosts and under different environmental conditions [15].
H. pylori eradication may not eliminate the risk of gastric cancer. Therapy of this bacteria may
be used in high-risk populations to reduce gastric cancer incidence. It can reverse many
biochemical, genetic, and epigenetic changes that H. pylori infection induces in the stomach
[16]. The major factors playing a pathogenic role in H. pylori-related non-cancer diseases are
host polymorphisms in genes involved in inflammation and protection against oxidative
damage, host exposure to dietary genotoxic agents, and bacterial genetic polymorphisms [17].
The study of host-bacterial interaction is key to detection the molecular and cellular pathways
involved and will lead to developing preventive and therapeutic modules against this
pathogen [18].
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Gastric inflammation nearly always precedes the development of peptic ulceration, and is a
critical component in initiating the multi-step progression towards gastric carcinogenesis due
to this interaction between these three factors [19].
H. pylori is spread from person to person by two routes, oral-oral and faecal-oral route [20].Food
prepared under less ideal conditions or exposed to contaminated water or soil may increase
the risk. Inadequate sanitation practices, low social class, and crowded or high-density living
conditions seem to be related to a higher prevalence of H. pylori infection. Therefore poor
hygiene and crowded conditions may facilitate transmission of infection among family
members Understanding the route of H. pylori transmission is important if public health
measures to prevent its spread. Iatrogenic transmission of H. pylori following endoscopy is the
only proven mode. The person-to-person mode of transmission is supported by the higher
incidence of infection among institutionalized children and adults and detection of H. pylori
DNA in vomitus, saliva, dental plaque, gastric juice, and feces. Waterborne transmission,
probably due to fecal contamination or contaminated well water, may be an important source
of infection, especially in parts of the world in which untreated water is common. H. pylori has
been isolated in domestic cats, housefly. However, evidence is lacking that H. pylori can be
transmitted to humans from flies that have been in contact with H. pylori-infected feces. Mode
of transmission of H. pylori is important to prevent its spread and identifying high-risk
populations [21, 22].
The pathogenesity of this bacterium depend on the production of several virulence factors.
The most important ones are CagA (cytotoxic associated gene A) and VacA (vacuolizating
cytotoxin A). The immunodominant CagA protein is encoded by genes called the cagA-PAI
(pathogenicity island), a 40 kb genomic fragment containing ORFs (open reading frames)
encoding approximately 31 genes that forms a type IV secretion system, which is found in 60–
70% of H pylori strains and can be divided into two regions, cag I and cag II, according to a
novel insertion sequence [23] This secretion system (T4SS) forms a pilus that delivers CagA,
an oncoprotein, into the cytosol of gastric epithelial cells through a rigid needle structure
covered by CagY, a VirB10-homologous protein and CagT, a Virb7-homologous protein, at the
base [24]. This is accomplished by a specialized adhesin of the pilus surface, the CagL protein,
which binds to and activates host cell integrins for subsequent delivery of CagA across the
host cell membrane. Injected CagA becomes tyrosine-phosphorylated by Src and Abl family
kinases and mimics a host cell protein in binding and activation of multiple signalling factors.
After the induction of membrane dynamics, actin cytoskeletal rearrangements and the
disruption of cell-to-cell junctions as well as proliferative, pro-inflammatory and anti-
apoptotic nuclear responses. All these signalling cascades contribute in H. pylori pathogenesis
[25]. Therefore, CagA remains the only identified effector mechanism that is translocated by
the T4SS of H. pylori into gastric epithelial cells where it induces host cell kinases that phos‐
phorylate tyrosine residues in CagA adjacent to the site of bacterial adhesion on the host gastric
epithelial cells, which in turn activate eukaryotic signal transduction pathways and cytoske‐
letal plasticity [26]. Wild-type H pylori ( not phosphorylation-resistant CagA )induced a growth
factor-like response in gastric epithelial cells. CagA formed a physical complex with the SRC
homology 2 domain (SH2)-containing tyrosine phosphatase SHP-2 in a phosphorylation-
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dependent manner and stimulated the phosphatase activity. On the other hand, the CagA
effect on cells was reproduced by constitutively active SHP-2. Thus, upon translocation, CagA
perturbs cellular functions by deregulating SHP-2 [27]. Injected CagA associates with the
epithelial tight-junction scaffolding protein ZO-1 and the transmembrane protein junctional
adhesion molecule, causing an ectopic assembly of tight-junction components at sites of
bacterial attachment, and altering the composition and function of the apical-junctional
complex. Long-term CagA delivery to polarized epithelia caused a disruption of the epithelial
barrier function and dysplastic alterations in epithelial cell morphology [28].
Regarding VacA, there is a significant polymorphism in this gene (vacA s, vacA i and vacA
m). There are two types of the s (s1 and s2), i (i1 and i2), and m (m1 and m2) regions of vacA
[29]. Three polymorphic subtypes, namely m1T, m1Tm2 and m2. The s1a/i1/m1Tm2 genotype
had a higher frequency of lymphoid follicle formation in the corpus than the s1a/i1/m1T and
s1a/i1/m2 strains while vacA s1/m1 strains are most closely associated with gastric carcinoma
[30]. The method PCR- genotyping from gastric biopsy had advantages over routine diagnostic
tools such as histological H. pylori detection, which has high interobserver variation, very much
depending on the experience of the pathologist, and over H. pylori culture, which is more time-
consuming, requires expertise, and is not always successful. In general, PCR-based techniques
show high sensitivity for H. pylori detection and permit further characterization of bacteria
virulence-associated genotypes. In archive materials, the genotyping of the vacA i region
allows the analysis of the H. pylori strains in the same biopsy specimen that can also be used
for histopathological evaluation, conferring a more reliable measurement of the effects of local
infecting strains. Another advantage of the use of archive materials is that it permits retro‐
spective studies to be performed without the need of H. pylori isolation from fresh biopsy
specimens [31].
In  most  cases,  the  infection  is  asymptomatic  and clinical  manifestation  appears  in  only
10-15% of infected individuals. This is due to virulence of H. pylori strains and host immune
response  to  this  bacterium  [32].  The  different  clinical  outcomes  may  be  explained  by
bacterial factors and the host immune responses. H. pylori induce a strong immune response
with infiltration of neutrophils, B- and T-cells into the gastroduodenal mucosa that fails to
clear the infection. Several virulence factors have been associated with the development of
gastroduodenal disease, e.g. the cytotoxin-associated gene A (CagA) and a vacuolating toxin
[33] individuals infected with strains lacking these genetic markers may still develop peptic
ulcers, and that many individuals infected with bacterial strains bearing these genotypes do
not develop any symptoms [34]. On other hand, the lower epithelial cytokine responses may
be  of  importance  for  the  pathogenesis  of  H.  pylori-induced  ulcers,  most  likely  can  be
explained  by  host  factors,  i.e.  mainly  a  decreased  ability  of  the  epithelium  to  produce
cytokines,  but  possibly  partly  also  down-regulation  by  regulatory  T  cells  [35].  H.  pylo‐
riinfection  induces  strong  antibody  responses  in  the  human  gastric  mucosa,  both  in
asymptomatic carriers and in ulcer patients [36].
This will shed a light on the immune response to H. pylori colonization and its effect on clinical
outcomes.
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2. Host immune response to H. pylori
The immune response towards bacterial pathogens can be divided into an innate and an
adaptive response.
2.1. Innate immune response to H. pylori
Recognition of bacterial antigenic molecules is mediated by TLRs (Toll-like receptors) that are
expressed by distinct cell types throughout the gastrointestinal tract, and play an important
role in regulation of the innate immune response especially TLR4 It is expressed on antigen-
presenting cells such as monocytes and dendritic cells. Bacterial contact with monocytes and
other APCs leads to the secretion of proinflammatory cytokines such as TNF-α (tumour
necrosis factor-α), IL (interleukin)-1β and IL-8. H. pylori infection has been shown to be
associated with increased levels of these cytokines which, in turn, act as local chemoattractants,
inducing granulocytic infiltration [37]. The gastric epithelia of children respond to H. pylori
infection by increasing the expression of TLR2, TLR4, TLR5, TLR9 and the cytokines IL-8, IL-10
and TNF-α that participate actively in innate immune responses [38]. Their role in the
progression of gastric lesions leading to cancer is associated with decreasing levels of TLRs
inhibitors and elevated TLRs levels throughout all the spectrum of lesions [39].
Figure 1. H. pylori pathogenesis, the inflammatory immune response and some of escape mechanisms [54].
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2.2. Adaptive immunity: cellular immune response and humoral response
2.2.1. Cellular immune response
Adaptive immune responses towards H. pylori infection have been developed after failure of
innate immune response to eliminate the pathogen. The immune response to Helicobacter
pylori is a versatile group of mechanisms involving responses that are both protective and
damaging to the host. The innate and the adaptive immune responses lead to damaging
inflammatory responses allowing for persistence of many infections [40]. H. pylori associated
inflammatory reaction is characterized by a mucosal infiltration of different cells like poly‐
morphonuclear leukocytes (PMN), T cells, macrophages, and plasma cells [41] in addition to
that H. pylori adheres to the cells of gastric mucosa and secretes different molecules that can
change gastric epithelial cell function [42]. Chronic active gastritis is associated with an
increased CD4/CD8 T-cell ratio within the gastric mucosa and accumulation of CD4+ T-helper
lymphocytes in the lamina propia of the gastric mucosa. H. pylori infection results in a Th1-
predominant host immune response in the gastric mucosa and induction of IFN- γ (interferon-
γ) and IFN-γ -related genes. A Th1-predominant immune response is associated with elevated
levels of the pro-inflammatory cytokines IL-12, IL-18 and TNF-α( [43]. Other cell that infiltrates
the gastric mucosa was Th17 which are CD4+ T cells associated with infections and inflamma‐
tion. Th17 are induced during both H. pylori infection and gastric cancer in the inflammatory
process of gastric stroma and may be an important link between inflammation and carcino‐
genesis [44]. The host genetic milieu contributes to the inflammatory response to H. pylori
infection is IL-1B. The IL-1B gene encodes the expression of IL-1β, a potent pro-inflammatory
cytokine and powerful inhibitor of gastric acid secretion that had a most important responsi‐
bility in initiating and amplifying the inflammatory response to H. pylori infection [45]. It had
been that IL-1 polymorphism had an effect on IL-1 production in gastric mucosa infected with
H. pylori [46]. This indicate that individual genetic polymorphism had an effect on disease
expression.
Yuceyar etal 2002 [47] found that there is no alteration in total T and B lymphocytes and CD4+
T, CD8+ T lymphocytes and natural killer cells of both duodenal ulcer and chronic antral
gastritis patients compared to normal persons. Although there was a slight increase in the
proportion of active T lymphocytes in duodenal ulcer and chronic antral gastritis groups
comparing to healthy subjects the difference was not statistically significant. This indicate that
there is no systemic alteration in the specific immune system in response to H. pylori in patients
with duodenal ulcer and chronic antral gastritis. Other study confirmed the systemic immune
response to helicobacters at the cellular level in patients with Helicobacter pylori infection by
leukocyte migration inhibition test was performed and a highly significant inhibitory effect on
leukocyte migration was found in patients with Helicobacter pylori infection [48].
2.2.2. Humoral immune response
H. pylori induce a strong specific systemic and local antibody response and infected individual
had antibodies against whole bacteria or part of it [49]and increase in plasma cells in gastric
mucosa which produce IgA [50]. Other important antibody was IgG that binds to H. pylori and
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enhance phagocytosis [51].This antibodies lead to complement activation by either classical or
alternative pathways [52]. In addition to that, the role of the secretory IgA is important in
neutralizing urease and VacA as well as inhibiting adherence of H. pylori to gastric mucosa
[53].The immune response to H. pylori can be summarized by figure -1- [54]. There is high
seroprevalence of H. pylori antibodies undervalue of past infection, the relation of the H.
pylori cytotoxin to gastric precancerous lesions is warranted. There is a strong mucosal IgA
response to H. pylori in non-neoplastic antral mucosa of gastric cancer patients irrespective of
the biopsy urease results [55].
2.2.2.1. Evasion of immune response by H. pylori
Helicobacter pylori is a gastric bacterial pathogen that evades host immune responses in vivo
by different mechanisms like inducing apoptosis of macrophages in association with altera‐
tions in the mitochondrial pathway [56].
Elimination of this key immunomodulatory cell may represent a mechanism employed by the
bacterium to evade host immune responses. It can survive intracellularly within macrophages
by interfering with lysosomal proteins, similar to Mycobacterium tuberculosis [57]. H. pylori like
many other pathogen escape the immune system by production an enzyme arginase that
prevent nitrous oxide production [58].
Vacuolating cytotoxin secreted by H. pylori has turned out to be a potent immunomodulatory
toxin. VacA-deficient H. pylori induced significantly higher expression of integrin-linked
kinase (ILK) and endothelial nitric oxygen synthase (eNOS), and significantly more production
of reactive oxygen species (ROS) in monocyte/macrophage-like U937 cells, as compared with
isogenic vacA+ H. pylori. Thus, vacA-deficient H. pylori appears to upregulate ILK expression,
which modulates the expression of eNOS and as a result, stimulates the production of ROS. It
is VacA that prevents such a process by inhibiting ILK expression, helping H. pylori escape host
immunoreaction and persist in gastric mucosa [59].
In addition to that, H. pylori LPS exhibits a reduced endotoxic potency in terms of pyrogenicity,
lethality, toxicity, mitogenicity and the lower immune response elicited by H. pylori LPS in
comparison with other enterobacterial LPS may represent an escape mechanism from the host
[60]. H. pylori, possess flagellin molecules that cannot be recognized by TLR5 that is important
for its survival [61]. H. pylori infection could alter cellular gene expression processes that evade
host immune mechanism by activating NF-κB and Wnt/β-catenin signaling pathway, disturb
metal ion homeostasis, and induce carcinogenesis [62].
VacA of H pylori act as an immunomodulator by interfering with the IL-2 signalling pathway
in T-cells by blocking Ca2+ mobilization and the activity of the Ca2+/calmodulin-dependent
phosphatase calcineurin [63]. It also interferes with antigen presentation mediated by MHC
class II [64]. VacA by itself act as immunosuppressive by a direct action on T-cells rather than
APCs [65]. VacA is a crucial element for H. pylori to escape from host immune defense by means
of differentially regulating the expression of some related genes by altering their mRNA
expression at different times [66].
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2.2.2.2. Vaccination against H. pylori infection
Helicobacter pylori can persist in the gastric mucosa of infected individuals for life, in the face
of chronic inflammation and low pH. Efforts to develop vaccines have largely failed and, in
the wake of emerging antibiotic resistance, novel therapeutic approaches have developed [67].
There is a consent that vaccines are essential to limit the severity of this infection. Great
development has been made since its detection 25 years ago the virulence factors and several
aspects of the pathogenesis of the H. pylori gastric diseases. Several key bacterial factors have
been identified: urease, vacuolating cytotoxin, cytotoxin-associated antigen, the pathogenicity
island, neutrophil-activating protein, and among others. These proteins, in their native or
recombinant forms, have been shown to confer protection against infectious challenge with
H. pylori in animal models. However, a quantity of clinical trials in healthy volunteers have
been conducted using urease given orally as a soluble protein or expressed in bacterial vectors
with limited results or a mixture of H. pylori antigens was reported to be highly immunogenic
in H. pylori-negative volunteers following intramuscular administration of the vaccine with
aluminium hydroxide as an adjuvant [69].
H. pylori is a mucosa-associated organism, it was initially thought that an IgA type anti-
Helicobacter antibody response would be essential for protective immunity [69]. An adjuvant
is an important component of any oral/mucosal vaccine as it is responsible for stimulating
immune system, but due to toxicities associated with these agents, there are currently no
suitable and safe adjuvants available for use in humans. Another important limitation to
effective oral immunization is that it requires multiple doses and a large amount of antigen
administration. These studies showed that mucosal immunity can be induced by oral or
intranasal routes of immunization. The intranasal route of immunization is similar to the oral
route in that it also requires the administration of bacterial antigen in conjunction with an
adjuvant multiple times [70].
Considering the side effects of oral adjuvants, researches have focused attention on making
oral immunization safe and effective for human usage. Thus, E. coli LT heat-labile toxin that
was used as an oral adjuvant in humans did show a significant decrease in gastric H. pylori
density but was associated with cramping and diarrhea [71]. Another approach is to use other
mucosal routes such as the nasal mucosa and the rectal mucosa for effective immunization.
When mice were immunized orally, rectally and intranasally in combination with E. coli heat-
labile toxin (LT) and subsequently challenged with purified H. pylori antigen, mice immunized
by either of the routes were found to be protected against this challenge compared with
controls. These studies showed that mucosal immunity can be induced by oral or intranasal
routes of immunization. The intranasal route of immunization is similar to the oral route in
that it also requires the administration of bacterial antigen in conjunction with an adjuvant
multiple times [72].
Although the intransal route of immunization seems the most efficient and effective route of
mucosal immunization, it still has some disadvantages histologic inflammation in the olfactory
bulb and cause paralysis of facial nerves [72]. Intranasal route could also result in oral ingestion
thus exposing the subject to various side effects and toxicities. Eriksson et al. [73] found that
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CTA1-DD adjuvant was to be safe for intranasal administration without any accumulation in
the nervous tissue.
Other modalities of administering vaccines such as the intraperitoneal (i.p.) and subcutaneous
(s.c.) routes are also being done. Mice were vaccinated i.p. using H. pylori antigen in combi‐
nation with aluminum hydroxide and upon rechallenge with H. pylori were found to confer
protection that was shown by absence of bacteria, both histologically and in culture of gastric
biopsy tissues. This immunity was noted to be antibody independent and achieved by IL-5-
secreting T cells [74]. The results of these experiments suggest that until a safe, effective, and
inexpensive mucosal (oral/nasal) vaccine becomes available, systemic immunizations should
be a consideration.
Urease is important as a vaccine antigen has been confirmed by numerous studies in mice,
ferrets, and non-human primates [75]. Urease conferred protection against helicobacter
infection when delivered either as a native protein or as an enzymatically inactive recombinant
protein [76]. Therapeutic immunisation with urease has recently been reported in ferrets
naturally infected with H. mustelae. [77]. Infection with H. mustelaeoccurs in ferrets soon after
weaning, persists for life, induces active chronic gastritis, and is associated with the develop‐
ment of ulceration in a subgroup of infected animals [78]. Thus, therapeutic immunisation is
possible in a natural setting of helicobacter infection, confirming that the inability of the natural
immune response to clear helicobacter infection can be overcome.
Other method of delivery of the antigen used in mice by immunisation with genetically
engineered bacteria expressing H. pylori antigens elicits a protective immune response against
gastric helicobacter infections. Immunisation with live bacterial vaccines usually requires only
one or two doses, does not depend on the addition of extra mucosal adjuvant, and the vaccine
can be produced at very low cost. Additional improvements to the vaccine should result from
a better understanding of the natural immune responses to helicobacter infection and of the
mechanisms by which vaccination restores protection [79].
Zhang etal, 2013 [80] used recombinant technology, Lactococcus lactis (L. lactis) could serve
as an antigen-delivering vehicle for the development of edible vaccine. They produced edible
UreB (urease B) vaccine derived from L. lactis against H. pylori. The UreB subunit is the most
effective and common immunogen of all strains of H. pylori. The UreB was produced as a
chimeric protein fused with IL-2 (human interleukin 2) as the mucosal adjuvant. Mucosal
immunization of mice with recombinant L. lactis NZ9000 containing the UreB-IL-2 protein
elicited more anti-UreB antibody that specifically bounded to the purified bacterial UreB
protein and more cytokines such as IFN-γ, IL-4, and IL-17, and had a lower H. pylori burden
and urease activity than control mice. These results suggest that the recombinant L. lactis
expressing UreB-IL-2 can be potentially used as an edible vaccine for controlling H. pylori
infection.
Altman etal, 2013 [81] demonstrated that synthetic glycoconjugates based on delipidated
lipopolysaccharide (LPS) of Helicobacter pylori and containing an α(1-6)-glucan chain induced
broadly cross-reactive functional antibodies in immunized animals. Thus, they prepared
glycoconjugates based on dextrans produced by lactic acid bacteria Leuconostoc mesenter‐
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oides B512F and consisting of linear α(1-6)-glucan chains with limited branching. Three
dextrans with averaged molecular masses of 5, 000 Da, 3, 500 Da and 1, 500 Da, respectively,
were modified with a diamino group-containing linker and conjugated to a carrier protein,
tetanus toxoid (TT) or diphtheria toxoid (DT. The conjugates were immunogenic in both rabbits
and mice and induced specific IgG responses against α(1-6)- glucan -expressing H. pylori LPS.
Studies performed with post-immune sera of mice and rabbits immunized with dextran-based
conjugates demonstrated cross-reactivity with LPS from typeable and non-typeable strains of
H. pylori and selected mutants. The post-immune sera from rabbits that received the conjugates
exhibited functional activity against α(1-6)-glucan-positive strains of H. pylori. These data
provide evidence that dextran-based conjugates may offer a simplified approach to the
development of carbohydrate-based vaccines against H. pylori.
Helicobacter pylori neutrophil-activating protein (NAP) is a toll-like receptor 2 (TLR2) agonist
and potent immunomodulator inducing Th1-type immune response. Iankov etal 2013
[82]studied the humoral immune response against NAP-tagged antigens, encoded by attenu‐
ated measles virus (MV) vector platform, in MV infection susceptible type I interferon receptor
knockout and human CD46 transgenic (Ifnarko-CD46Ge) mice. Immunogenicity of MV
expressing a full-length human immunoglobulin lambda light chain (MV-lambda) was
compared to that of MV expressing lambda-NAP chimeric protein (MV-lambda-NAP). MV-
lambda-NAP immunized Ifnarko-CD46Ge mice developed significantly higher (6-20-fold)
anti-lambda ELISA titers as compared to the MV-lambda-immunized control animal group,
indicating that covalently-linked NAP co-expression significantly enhanced lambda immu‐
nogenicity. In contrast, ELISA titers against MV antigens were not significantly different
between the animals vaccinated with MV-lambda or MV-lambda-NAP. NAP-tagged antigen
expression did not affect development of protective anti-measles immunity. Both MV-lambda
and MV-lambda-NAP-immunized groups showed strong virus neutralization serum titers in
plaque reduction microneutralization test. They concluded that MV-encoded lambda-NAP is
highly immunogenic as compared to the unmodified full-length lambda chain. Boost of
immune response to poor immunogens using live vectors expressing NAP-tagged chimeric
antigens is an attractive approach with potential application in immunoprophylaxis of
infectious diseases and cancer immunotherapy.
An important consideration in the development of subunit vaccines is the loss of activity caused
by physical instability of the protein. CagL is a protein present in strains of H. pylori. It
contributes to bacterial adherence via α5β1 integrin, thereby making it an attractive subunit
vaccine candidate. Choudhari etal, 2013 [83] used CagL in different pH and temperature
conditions using a variety of spectroscopic techniques. Stability was assessed in terms of
transition temperature with the accumulated data, and then incorporated into an empirical
phase diagram (EPD) that provided an overview of CagL physical stability. These analyses
indicated maximum CagL stability at pH 4-6 up to 40°C in the absence of excipient. Using this
EPD analysis, aggregation assays were developed to screen a panel of excipients with some
found to inhibit CagL aggregation. These analyses will help in the formulation of a stable
vaccine against H.pylori.
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Helicobacter pylori is a major human pathogen that colonizes the stomach and is the lead
etiological agent for several pathologies. Sutton P and Chionh YT 2013 [84] demonstrated that
effective vaccine against these bacteria would be invaluable for protecting against gastric
adenocarcinoma. However, the development of such a vaccine has stalled and the field has
progressed little in the last decade. The key problems that are preventing the development of
a H. pylori vaccine. Primarily, this involves the inability to produce a completely protective
immune response. The knock-on effects of this include a loss of industry investment. Over‐
coming these problems will likely involve defeating the immune-evasion defenses of H.
pylori, in particular the mechanism(s) by which it evades antibody-mediated attack.
Chronic H. pylori infection can be successfully eradicated by intragastric vaccination with H.
pylori antigens such as recombinant VacA and CagA, which were administered together with
a genetically detoxified mutant of the heat-labile enterotoxin of Escherichia coli (referred to as
LTK63), in which the serine in position 63 was replaced by a lysine. The therapeutic vaccination
confers efficacious protection against reinfection [85]. Vaccines against Helicobacter pylori could
circumvent the problem of increasing antibiotic resistance. They would be particularly useful
in developing countries, where re-infection rates are high following standard eradication
regimes. The vaccine could be given orally with an H. pylori whole cell sonicate preparation
and cholera toxin adjuvant. Protection was associated with increased serum H. pylori IgG
antibodies. In this type of vaccine the levels of gastric IL-12p40 and IFN-gamma transcripts
were significantly decreased. Gastric IL-10 and TGF-beta transcripts were found only at
relatively low levels [86]. Other type of vaccines were used a recombinant antigen ureB138 (a
segment of the beta-subunit of urease) against Helicobacter pylori infection [87]. Using mucosal
vaccination with H. pylori antigens when given together with cholera toxin (CT) adjuvant, but
not without adjuvant, can induce protective immune responses against H. pylori infection.
However, the toxicity of CT prevents its use as a mucosal adjuvant in humans. The using a
nontoxic double mutant Escherichia coli heat-labile toxin, LT(R192G/L211A) (dmLT), as a
mucosal adjuvant in an experimental H. pylori vaccine and compared it to CT in promoting
immune responses and protection against H. pylori infection. Immunization via the sublingual
or intragastric route with H. pylori lysate antigens and dmLT resulted in a significant decrease
in bacterial load after challenge. Cellular immune responses in the sublingually route resulting
in enhanced in vitro proliferative and cytokine responses from spleen and mesenteric lymph
node cells to H. pylori antigens. Thus, dmLT is an attractive adjuvant for inclusion in a mucosal
vaccine against H. pylori infection [88].
3. Conclusions
Helicobacter infection is an important cause of cancer development. Immune response to this
bacterial infection is playing an important role in gastric inflammation. The infection may be
innocent or subclinical. Therefore, frequent patients screening for this bacteria and eradication
of Helicobacter spp. is very crucial. Researches about these bacteria are very essential starting
from laboratory animal to application of the researches from lab bench to clinic. Innate and
adaptive immune responses of the host are seriously significant for the development of new
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plans to prevent the development of H. pylori-induced gastroduodenal disease and production
a vaccine to eradicate this infection. It will be necessary to determine the feasibility of using
different epitopes extracted from H. pylori in a vaccine design.
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